

WHSC2 Antibody (Center) Blocking Peptide
Synthetic peptide
Catalog # BP14802c**Specification**

WHSC2 Antibody (Center) Blocking Peptide - Product InformationPrimary Accession [Q9H3P2](#)**WHSC2 Antibody (Center) Blocking Peptide - Additional Information****Gene ID** 7469**Other Names**

Negative elongation factor A, NELF-A, Wolf-Hirschhorn syndrome candidate 2 protein, NELFA, WHSC2

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

WHSC2 Antibody (Center) Blocking Peptide - Protein Information**Name** NELFA**Synonyms** WHSC2**Function**

Essential component of the NELF complex, a complex that negatively regulates the elongation of transcription by RNA polymerase II. The NELF complex, which acts via an association with the DSIF complex and causes transcriptional pausing, is counteracted by the P-TEFb kinase complex.

Cellular Location

Nucleus.

Tissue Location

Ubiquitous. Expressed in heart, brain, placenta, liver, skeletal muscle, kidney and pancreas. Expressed at lower level in adult lung. Expressed in fetal brain, lung, liver and kidney

WHSC2 Antibody (Center) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

WHSC2 Antibody (Center) Blocking Peptide - Images

WHSC2 Antibody (Center) Blocking Peptide - Background

This gene is expressed ubiquitously with higher levels in fetal than in adult tissues. It encodes a protein sharing 93% sequence identity with the mouse protein. Wolf-Hirschhorn syndrome (WHS) is a malformation syndrome associated with a hemizygous deletion of the distal short arm of chromosome 4. This gene is mapped to the 165 kb WHS critical region, and may play a role in the phenotype of the WHS or Pitt-Rogers-Danks syndrome. The encoded protein is found to be capable of reacting with HLA-A2-restricted and tumor-specific cytotoxic T lymphocytes, suggesting a target for use in specific immunotherapy for a large number of cancer patients. This protein has also been shown to be a member of the NELF (negative elongation factor) protein complex that participates in the regulation of RNA polymerase II transcription elongation.

WHSC2 Antibody (Center) Blocking Peptide - References

Rose, J.E., et al. Mol. Med. 16 (7-8), 247-253 (2010) ; Narita, T., et al. Mol. Cell 26(3):349-365 (2007) ; Olsen, J.V., et al. Cell 127(3):635-648 (2006) ; Beausoleil, S.A., et al. Nat. Biotechnol. 24(10):1285-1292 (2006) ; Ping, Y.H., et al. J. Biol. Chem. 276(16):12951-12958 (2001)